Gemtuzumab Ozogamicin (GO)

DRUG4 trials

Sponsors

Eastern Cooperative Oncology Group, Versailles Hospital, Brown University

Conditions

Acute Myeloid LeukemiaLeukemiaLeukemia, Myeloid, Acute

Phase 2

Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4

CompletedNCT02473146

Versailles HospitalAcute Myeloid Leukemia

Start: 2015-11-18End: 2023-09-07Updated: 2024-02-02

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Active, not recruitingNCT03374332

Brown UniversityAcute Myeloid Leukemia

Start: 2019-12-31End: 2024-09-30Updated: 2024-02-08

Phase 3

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia

CompletedNCT00049517

Eastern Cooperative Oncology GroupLeukemia

Start: 2002-12-19End: 2019-12-31Updated: 2023-06-15

Unknown Phase

Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®

Versailles HospitalLeukemia, Myeloid, Acute

Start: 2017-11-01End: 2019-03-01Target: 300Updated: 2018-01-24

Related Papers

Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Blood2023-11-02

Characteristics and prognostic impact of<i>IDH</i>mutations in AML: a COG, SWOG, and ECOG analysis

Blood Advances2023-06-0250 citations

Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG‐ACRIN analysis

Cancer2023-04-258 citations

Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling

Leukemia Research2022-10-217 citations

Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study

Blood2021-11-055 citations

Prognostic Significance of <i>DDX41</i> Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study

Blood2021-11-051 citations

Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin

Blood2021-11-051 citations

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Blood2019-11-131 citations

Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614)

Blood2018-11-29

ANTHRACYCLINE DOSE INTENSIFICATION IN DIFFUSE LARGE <scp>B</scp>‐CELL LYMPHOMA

Hematological Oncology2017-06-01

A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia.

2016-06-0115 citations

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Blood2016-01-11127 citations

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

Blood2014-12-06

Anthracycline dose intensification in acute myeloid leukemia.

2009-09-01687 citations